Neos Therapeutics, Inc.

neostx.com

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ZERION PHARMA AND HOVIONE EXTEND PARTNERSHIP TO COVER USE OF THE DISPERSOME® TECHNOLOGY PLATFORM IN NUTRACEUTICALS

Zerion Pharma and Hovione | August 24, 2022

news image

Hovione and Zerion Pharma announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology for the development and commercialization of cert...

Read More

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

news image

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More

Business Insights, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

news image

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More

Business Insights

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

news image

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More
news image

Pharma Tech

ZERION PHARMA AND HOVIONE EXTEND PARTNERSHIP TO COVER USE OF THE DISPERSOME® TECHNOLOGY PLATFORM IN NUTRACEUTICALS

Zerion Pharma and Hovione | August 24, 2022

Hovione and Zerion Pharma announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology for the development and commercialization of cert...

Read More
news image

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More
news image

Business Insights, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More
news image

Business Insights

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More

Resources

resource image

Business Insights, PHARMA TECH

Tabletop Aluminum Foil Induction Sealer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us